SMARCA2 and neoplasm: Given that 5/44 SCCOHT retained some degree of SMARCA4 expression, we explored whether these SMARCA4-positive tumours may demonstrate other SWI/SNF alterations, in particular, loss of the other closely related catalytic domain, SMARCA2.